OTTAWA, Jan. 30, 2013 /CNW/ -
The issue:
Arbonne International Distribution Inc. is voluntarily recalling one lot (lot 043904) of its RE9 Advanced for Men Facial Moisturizer SPF 20 Sunscreen due to microbial contamination. Product testing undertaken by the company detected bacteria (Aerococcus viridans) that may pose serious health risks to people, especially those with weakened immune systems.
Who is affected:
Canadians, who have purchased or used this product, especially those with weakened immune systems, such as those with HIV/AIDS.
What should you do:
|
What Health Canada is doing:
Health Canada is monitoring the recall and the company's investigation to identify and address the root cause of the contamination.
No adverse reactions involving the use of this product have been reported to Health Canada. The company has also confirmed it has received no adverse reactions reports involving the affected product to date.
Background:
The bacterium identified in the tested samples is Aerococcus viridans, which has been associated with infections of the blood, joints, lining of the heart and valves, and with meningitis. Potentially serious infection may result when the affected product is used in those with weakened immune systems and those with HIV/AIDS, as well as in those with damaged skin, and cuts from shaving.
The product is sold through Arbonne International Distribution's network of independent sales consultants.
For more information:
Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or toll free at 1-866-225-0709.
Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.
How to report side effects to health products to Health Canada:
Stay connected with Health Canada and receive the latest advisories and product recalls using social media tools.
Également disponible en français
PDF available at: http://stream1.newswire.ca/media/2013/01/30/20130130_C9809_DOC_EN_23129.pdf
SOURCE: Health Canada
Share this article